Cynata Therapeutics Ltd (ASX: CYP) Share Price and News

Dr. Wotton was President and CEO of Obsidian Therapeutics, Founding CEO of Sigilon Therapeutics (acquired by Lilly) and President and CEO of Ocata Therapeutics, Inc. which was acquired by Astellas in 2016. Prior to Ocata, he served as President and CEO of Antares Pharma Inc. Prior to joining Antares, he was the CEO of Topigen Pharmaceuticals. Earlier in his career, he held executive positions at SkyePharma plc, Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. He is a member of the board of Vericel Corporation , Chairman of Dimension Inx. and Chairman of Kytopen Inc.

Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.

Dr Brooke co-founded GBS Venture Partners in 1996 and has more than 30 years' venture capital experience. He was formerly President of Medvest Inc., a US-based venture capital group he founded with Johnson & Johnson. His experience includes company formation and acquisitions as well as public listings on NYSE, NASDAQ and ASX exchanges. From 2009 until 2015, he was a director of the Victoria Workcover Authority. He also works with a number of other entities, including as a consultant to BioScience Managers.

Ms Rolfe brings more than two decades of legal, governance and management experience across multiple sectors, including regulated industries and global businesses. She is also a commissioner for the NSW Independent Casino Commission, a statutory authority. Previously, she was General Counsel & Company Secretary of Link Group. Prior to that, she founded the governance consultancy Company Matters and worked as in-house counsel at Qantas and in private practice at Mallesons Stephen Jaques (now King & Wood Mallesons).

Dr Kelly has served as Senior Director, Drug Development at Biota Pharmaceuticals Inc. Prior to joining Biota, he was Vice President, Regulatory and Clinical at Mesoblast Ltd. He has also held a variety of regulatory and project management positions with Kendle International, Amgen and AstraZeneca.